Synthetic endogenous cannabinoids analogues and uses thereof

US6531636B1 · kind B1 · utility

Assignee

• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL

Inventors

• Raphael Mechoulam · Jerusalem, IL
• Esther Fride · Beer Sheva, IL
• Shimon Ben Shabat · Jerusalem, IL
• Tzviel SHESKIN · Haifa, IL
• Aviva Breuer · Jerusalem, IL

Key dates

• Filing date: Oct 3, 2000
• Grant date: Mar 11, 2003
• Expiry date: Oct 6, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.